Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime

NCT02532140 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: WCK 5107 250 mg to 2000 mg
DRUG: Cefepime 2000 mg
DRUG: WCK 5107 1000/2000 mg with Cefepime 2000 mg combination
DRUG: Placebo

Sponsor

Wockhardt

Collaborators

[object Object]